Recent advancements in Alzheimer’s disease research have yielded breakthroughs in biomarkers, diagnostic criteria, and disease-modifying trials, culminating in the approval of drugs capable of eliminating amyloid plaques from the brain. While lecanemab gained approval from the US FDA and is expected to receive conventional approval soon, the clinical benefits of aducanumab remain uncertain, with ongoing trials focusing on cognitive decline. The implementation of these treatments for Alzheimer’s disease research requires meticulous preparation within healthcare systems to ensure safe delivery and equitable access, particularly in regions with aging populations, necessitating the establishment of protocols and guidelines for effective management.1
Continue reading here.
References
- Neurology, N. L. (2023). Treatment for Alzheimer’s disease: time to get ready. Lancet Neurology, 22(6), 455. https://doi.org/10.1016/s1474-4422(23)00167-9
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
